ASH 2025 | A ROCCA database analysis of the real-world administration of obe-cel and brexu-cel for R/R ALL
Yannis Valtis, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the findings of a ROCCA database analysis examining patient characteristics, toxicity, and response after real-world administration of commercial CAR T-cell therapies, specifically brexucabtagene autoleucel (brexu-cel) and obecabtagene autoleucel (obe-cel), for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Valtis highlights that patient characteristics were similar between the two groups, and that obe-cel was associated with lower rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
